Erschienen in:
16.10.2019 | ASO Author Reflections
ASO Author Reflections: Lobe-Specific Lymph Node Dissection for Early-Stage Non-small Cell Lung Cancer: A Long Way to Go in the Era of Minimally Invasive Thoracic Surgery
verfasst von:
Han-Yu Deng, MD, Qinghua Zhou, MD
Erschienen in:
Annals of Surgical Oncology
|
Ausgabe 2/2020
Einloggen, um Zugang zu erhalten
Excerpt
Current guidelines recommend systematic lymph node (LN) dissection (SLND) or sampling for treating early-stage non-small cell lung cancer (NSCLC).
1 However, the optimal extent of LN dissection for early-stage NSCLC remains controversial, as lobe-specific LN dissection (L-SLND) has been recently advocated as a minimally invasive alternative to SLND for treating early-stage NSCLC.
2 Also, our previous study showed that L-SLND could yield a lower risk of postoperative morbidity than SLND without compromising oncological outcomes.
2 However, in previous studies, the extent of L-SLND also remains unclearly defined without widely accepted recommendation.
3 Therefore, how to perform L-SLND for early-stage NSCLC requires further in-depth investigation. …